同源重组修复/乳腺癌易感基因(BRCA)改变对真实世界转移性前列腺癌生存的影响
在196例经HRR筛查的转移性前列腺癌患者中,61例(31%)存在HRR改变、40例(20%)存在BRCA1/2改变。HRR阳性与阴性患者的总生存期(OS)存在显著差异,多因素校正后HRR/BRCA1/2改变与更差OS相关;mCRPC中BRCA1/2突变未用PARPi者OS较用PARPi者更差(中位33 vs 48个月,P<0.03)。
要点
- 真实世界血样和组织检测中HRR改变发生率为31%,BRCA1/2改变为20%。
- 激素敏感期HRR阳性、BRCA1/2阳性与HRR阴性中位OS分别为63、57、113个月(P≤0.01)。
- mCRPC期BRCA1/2突变未用PARPi者中位OS 33个月,用PARPi者48个月(P<0.03)。
核心结论
- 在真实世界临床环境中,采用血样和组织检测时HRR改变发生率较高。
- HRR/BRCA改变患者结局更差,HRR/BRCA阳性mCRPC患者用与不用PARPi相比HRR/BRCA阴性患者存在显著OS差异。
研究设计与样本
- 对全部经HRR筛查的转移性前列腺癌患者进行基线特征采样,共纳入196例符合条件患者。
- 采用Kaplan-Meier估计和多因素Cox回归模型预测HRR/BRCA1/2改变对OS的影响。
主要发现
- 196例中61例(31%)存在任何HRR改变,40例(20%)存在BRCA1/2改变。
- HRR改变中,BRCA1/2为40例(66%),ATM为6例(10%),CHEK2为5例(8.2%),CDK12为4例(6.6%),FANCA为2例(3.3%),其他突变阳性为4例(6.6%)。
- 其中30%接受了PARPi治疗。
- 激素敏感前列腺癌中位OS:HRR阳性63个月 vs BRCA1/2阳性57个月 vs HRR阴性113个月(P≤0.01)。
- mCRPC中位OS:HRR阳性42个月 vs BRCA1/2阳性41个月 vs HRR阴性70个月(P≤0.01)。
关键数值与推荐
- HRR阳性、BRCA1/2阳性与HRR阴性在激素敏感前列腺癌中的中位OS分别为63、57、113个月(P≤0.01)。
- HRR阳性、BRCA1/2阳性与HRR阴性在mCRPC中的中位OS分别为42、41、70个月(P≤0.01)。
- mCRPC中BRCA1/2突变未用PARPi者与用PARPi者的中位OS分别为33和48个月(P<0.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate alterations of homologous recombination repair (HRR) and especially BReast CAncer 1/2 (BRCA1/2) gene on overall survival (OS). Moreover, to explore the effect of inhibition of poly(ADP-ribose)-polymerase (PARPi) as systemic therapy for metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: Of all HRR-screened patients with metastatic prostate cancer, baseline characteristics were sampled. Kaplan-Meier estimates and multivariable Cox regression models predicted the effect of HRR/BRCA1/2 alterations on OS. RESULTS: Of 196 eligible patients, 61 (31%) harboured any HRR and 40 (20%) BRCA1/2 alterations. Of HRR alterations, 40 (66%) vs six (10%) vs five (8.2%) vs four (6.6%) vs two (3.3%) vs four (6.6%) were BRCA1/2 vs Ataxia-telangiectasia mutated kinase (ATM) vs checkpoint kinase 2 (CHEK2) vs cyclin-dependent kinase 12 (CDK12) vs Fanconi anaemia complementation Group A (FANCA) vs positive for other mutations. Of these, 30% received a PARPi. OS differed significantly between HRR-positive vs -negative patients. Specifically in hormone-sensitive prostate cancer, the median OS was 63 (HRR positive) vs 57 (BRCA1/2 positive) vs 113 months (HRR negative) (P ≤ 0.01). In mCRPC, OS was 42 (HRR positive) vs 41 (BRCA1/2 positive) vs 70 months (HRR negative) (P ≤ 0.01). HRR and BRCA1/2 alterations were associated with worse OS after multivariable adjustment. Finally, patients with mCRPC with BRCA1/2 mutation treated without PARPi harboured worse OS than patients with BRCA1/2 mutation and PARPi therapy (median OS: 33 vs 48 months, P < 0.03). CONCLUSION: Incidence of HRR alteration in a clinical real-world setting is high when using blood- and tissue-based tests. Patients with HRR/BRCA alterations have worse outcomes resulting in significant OS differences between HRR/BRCA-positive patients with mCRPC with and without PARPi usage vs HRR/BRCA-negative patients.
引用
- Wenzel M, Hoeh B, Koll F, et al. Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer. BJU Int. 2024. PMID: 38982928. doi:10.1111/bju.16462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。